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Incremental advances in medical technology, such as the development of sensitive hormonal assays for routine
clinical care, are the drivers of medical progress. This principle is exemplified by the creation of the concept of
multiple endocrine neoplasia type 2, encompassing medullary thyroid cancer, pheochromocytoma, and primary
hyperparathyroidism, which did not emerge before the early 1960s. This review sets out to highlight key
achievements, such as joint biochemical and DNA-based screening of individuals at risk of developing multiple
endocrine neoplasia type 2, before casting a spotlight on current challenges which include: (i) ill-defined upper
limits of calcitonin assays for infants and young children, rendering it difficult to implement the biochemical part of
the integrated DNA-based/biochemical concept; (ii) our increasingly mobile society in which different service
providers are caring for one individual at various stages in the disease process. With familial relationships
disintegrating as a result of geographic dispersion, information about the history of the origin family may become
sketchy or just unavailable. This is when DNA-based gene tests come into play, confirming or excluding an
individual’s genetic predisposition to multiple endocrine neoplasia type 2 even before there is any biochemical or
clinical evidence of the disease. However, the unrivaled molecular genetic progress in multiple endocrine neoplasia
type 2 does not come without a price. Screening may uncover unknown gene sequence variants representing either
harmless polymorphisms or pathogenic mutations. In this setting, functional characterization of mutant cells in vitro
may generate helpful ancillary evidence with regard to the pathogenicity of gene variants in comparison with
established mutations.
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INTRODUCTION
Incremental advances in medical technology, such as the
development of sensitive hormonal assays for routine
clinical care, are the drivers of medical progress. This
principle is exemplified by the creation of the concept of
multiple endocrine neoplasia type 2 (MEN2), which did not
emerge before the early 1960s (1). This hereditable syn-
drome combines three distinct disease entities into one
clinical syndrome: medullary thyroid cancer (MTC); pheo-
chromocytoma; and primary hyperparathyroidism (2,3).
MEN2B patients who do not have primary hyperparathyr-
oidism also develop conjunctival, corneal, buccal, lip and
tongue neuromas, intestinal ganglioneuromas (dubbed
‘‘pseudo-Hirschsprung’s disease’’), and skeletal anomalies
subsumed under the designation of ‘‘Marfanoid habitus’’ as
they grow older (2–4).
Before this landmark event, individuals operated on for
MTC used to be diagnosed with papillary, follicular, or
undifferentiated thyroid cancer. After completing their
fourth decade of life, some of these patients succumbed to
metastatic MTC or to acute hypertensive crisis owing to
adrenergic hormonal excess from a previously undetected
pheochromocytoma. In the absence of a postmortem
examination, these deaths were frequently ascribed to acute
cardiovascular or cerebrovascular events. Without clinical–
pathologic characterization of the disease, targeted inter-
ventions are difficult, if not impossible, to carry out at an
early stage in the disease process.
BIOCHEMICAL SCREENING
The widespread availability of commercial calcitonin and
catecholamine assays in the 1960s completely changed the
scene, enabling biochemical screening of asymptomatic
individuals from MEN2 families who were suspected to
harbor C-cell disease and adrenal medullary disease (5). At
the very beginning, calcitonin screening, augmented
through stimulation with intravenous bolus injections of
pentagastrin or calcium gluconate short infusions, was
largely cross-sectional, including kindreds of various age
groups at different stages of tumor development (5). With
the increasing inclusion of asymptomatic infants and young
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113children at risk of developing MEN2 tumors, the focus of
the screening programs shifted toward longitudinal obser-
vation of family members (6). This prompted biochemical
screening of individuals at risk of developing MEN2 over
many years who were slated for preemptive thyroidectomy
as soon as basal serum calcitonin levels exceeded the upper
normal limit of the assay. With the exception of a few false-
positives from physiologic C-cell disease of the thyroid or
calcitonin-secreting small cell lung cancer or pancreatic
neuroendocrine cancer (7), this approach worked fairly well,
reducing the number of patients newly diagnosed with
advanced MTC (5,6). As a result, family members from the
younger generations were found to have more localized
disease (‘‘anticipation phenomenon’’), as opposed to the
metastatic disease that used to haunt earlier generations.
This breakthrough in the management of MEN2 patients
is beautifully illustrated in Figure 1 with the pedigree of an
MEN2A family of Transylvanian Saxons (ethnic Germans
whose ancestors colonized Sibiu (Hermannstadt) county in
present-day Romania during the 13th century). The first two
affected individuals, I-2 and II-3, developed huge neck
lumps (presumably MTC) and severe hypertension (pre-
sumably due to pheochromocytoma), causing aphonia
(presumably as a result of recurrent laryngeal nerve
invasion) and hemiplegia at the age of 42 years (presumably
following cathecholamine excess) in individual II-3. Both
MTC and pheochromocytoma went unrecognized as such
by the rural Communist healthcare system, so that the
diagnosis of MEN2A was not made at the time (Figure 1,
shaded area). After the fall of the Eastern bloc in 1989, the
whole family migrated to Germany where individuals III-7
and IV-9 were found to harbor node-positive MTC and
pheochromocytoma at the age of 36 and 14 years in 1994 and
1995, respectively (Figure 1). Unfortunately, several family
members declined screening.
DNA-BASED SCREENING
The 1993 and 1994 discoveries of RET (REarranged during
Transfection) as the susceptibility gene for MEN2 ushered in
the molecular era (8–10). Owing to the need for genetic
association studies for unequivocal cases of MEN type 2,
higher risk mutations in codon 918 (the classic MEN2B
mutation; American Thyroid Association/ATA D), codon
634 (the classic MEN2A mutation; ATA C) and codons 609,
611, 618, 620, and 630 (ATA B) were overrepresented in the
International MEN2 Consortium (2). The subsequent scan-
ning of the RET proto-oncogene for additional mutations
identified more RET mutations in codons 768, 790, 791, 804,
and 891 between 1995 and 1998 (11–14). These milder
mutations were often associated with familial MTC only, an
abortive form of MEN2.
Figure 1 - Multigenerational Ethnic German C634R Family from Romania.
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114GENOTYPE–PHENOTYPE CORRELATIONS
Transformation from hyperplasia to neoplasia
The RET proto-oncogene encodes for a transmembrane
tyrosine kinase receptor. The constitutive (i.e., genetically
encoded) activation of the mutated RET receptor protein is
believed to cause, in decreasing frequency, hyperplasia of
the parafollicular C-cells, adrenal medullary cells, and
parathyroid chief cells (3). A second mutation in one of
these neuroendocrine cells (‘‘second hit’’) is thought to
cause MTC (C-cell cancer), pheochromocytoma, and pri-
mary hyperparathyroidism. Because the acquisition of
somatic mutations by these cells reflects the play of chance,
the development of the various MEN2 components can vary
tremendously even among members of the same family,
compromising predictions regarding the age by which the
various MEN2 components will have developed. As a rule,
the weaker the transforming activity of the inherited RET
mutation, the more variable will be the clinical presentation
(phenotype) of the various MEN2 components (3,15,16),
with steep gradients from highest risk ATA-D to very high-
risk ATA-C, high-risk ATA-B, and lowest risk ATA-A
mutations (Table 1). Carriers of the last two groups of
mutations may develop familial MTC only.
Youngest age of tumor development
A systematic review of the literature (2,15–28), focused on
the youngest carrier age at which a given MEN2-related
tumor was ever reported, yielded the following chart of
earliest tumor development (Table 1): medullary thyroid
cancer as early as age 2 months (carriers of mutations in
codon 918), 10 months (carriers of mutations in codon 634),
12 months (carriers of mutations in codon 630), 4–7 years
(carriers of mutations in codons 609, 611, 618 and 620) and
9–21 years (carriers of mutations in codons 533, 768, 790,
791, 804 and 891); pheochromocytoma as early as age 12
years (carriers of mutations in codon 918 and 634), 19–30
years (carriers of mutations in codons 609, 611, 618, and
620), and 28–59 years (carriers of mutations in codons 768,
790, 791, 804, and 891); primary hyperparathyroidism as
early as 5 years (carriers of mutations in codon 634), 34–41
years (carriers of mutations in codons 609, 611, 618, and
620), and 38–54 years (carriers of mutations in codons 533,
768, 790, 791, 804, and 891), but for unknown reasons, never
in MEN2B patients (carriers of mutations in codon 918).
With more data set to be forthcoming, the current ATA
assignments of the rare RET mutations in codon 630
(currently ATA-B) and 883 (currently ATA D) may need
to be revised.
Youngest age of node-positive MTC
Another literature review of the youngest age of carriers
harboring lymph node metastases from MTC revealed a
comparable pattern (16). Barring rare exceptions, lymph
node metastases have not yet developed before age 2 years
(carriers of mutations in codon 918), not before age 5 years
(carriers of mutations in codon 634) and 15 years (carriers of
mutations in codons 630) and not before age 20 years in the
remaining RET carriers.
Window of opportunity for cure
The lead time provided by early screening of infants and
young children from RET families defines a ‘‘window of
opportunity’’, setting the time frame within which total
thyroidectomy alone will eliminate all C-cell disease (3). If
this time frame has been exceeded, systematic dissection of
the central and lateral lymph nodes on either side of the
neck is unavoidable. In this situation, the patient’s prospects
of cure fall from 95% with no lymph node metastases to
57–31% with 1–10 lymph node metastases and 0–4% with
.10 lymph node metastases (29,30).
INTEGRATED DNA-BASED/BIOCHEMICAL CONCEPT
OF EARLY THYROIDECTOMY
The impossibility of anticipating the development of the
various MEN2 components has prompted both overtreatment
Table 1 - RET genotype–phenotype relationships and ATA recommendations for thyroidectomy.
ATA
group
RET
genotype
Relative frequency of genotype
among RET families (%)
RET phenotype:
youngest age at tissue diagnosis
(years) (2,15–28)
ATA recommendations for
thyroidectomy (31)
Exon Codon
Germany
(n=140) (19)
Italy
(n=235) (22) MTC PCC pHPT
DNA
based
b+stCT
based
D 16 918 15 8 0.2 12 – ASAP (#1 year) if q
15* 883* 0 0.4 39* 39* N/A
C 11 634 41 37 0.8 12 5 ,5 years if q
B1 1 { 630{ 0.7 2 1{ –3 2 ,5 years (may delay if b+stCT WNL) if q
10 620 7 4 5 19 N/A
10 618 5 6 5 19 41
10 611 1 0.4 7 30 40
10 609 0.7 3 4 19 34
A 8 533 0{ 0{ 21 35 N/A May delay .5 years if b+stCT WNL if q
13 768 1 4 9 59 N/A
13 790 12 3 10 28 N/A
13 791 7 ,1 1 53 83 8
14 804 6 22 6, 12 28–33 54
15 891 2 10 39 39 N/A
ASAP=as soon as possible; ATA=American Thyroid Association; b+stCT=basal and stimulated serum calcitonin levels; MTC=medullary thyroid cancer;
PCC=pheochromocytoma; pHPT=primary hyperparathyroidism; RET=REarranged during Transfection.
*May need regrouping if confirmed in subsequent studies (ATA group A?).
{May need regrouping if confirmed in subsequent studies (ATA group C?).
{May be more common in Brazilians of Catalan/Spanish ancestry (17) and the Greek population (20).
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116(based on the above worst-case scenarios) and undertreatment
(practicing the law of averages) of gene carriers. Although the
respective RET mutation sets the stage for tumor develop-
ment, defining a time corridor, this corridor often is too wide
to be useful for individual decisions with regard to the timing
of prophylactic thyroidectomy.
This imperfection of the DNA-based approach prompted
researchers to build on the strengths of the DNA-based
and biochemical screening programs, giving rise to the
integrated DNA-based/biochemical concept of early thyr-
oidectomy (16). Herein, biochemical information (basal
serum calcitonin levels) is utilized to spot imminent or
early malignant transformation from C-cell hyperplasia to
MTC while it is still confined to the thyroid gland. There is
good evidence to suggest that MTC has not developed as
long as basal calcitonin levels remain within normal limits.
No more than one-third of pediatric RET gene carriers with
increased basal calcitonin levels are believed to harbor
occult MTC (16). It may be interesting to note that lymph
node metastases have not yet been reported with basal
serum calcitonin levels #40 pg/ml (upper normal limit
,10 pg/ml) (16,26,31).
What precisely constitutes a normal or elevated serum
calcitonin level for infants and young children remains to be
determined. As a rule, calcitonin levels tend to be higher in
infants younger than 6 months but are thought to
approximate to adult levels by the age of 3 years (32). In
male and female children older than 6 months (i.e., aged 1–9
years), normal calcitonin values as high as 17 pg/ml and
8.5 pg/ml, respectively, have been noted, exceeding the
manufacturer’s upper normal limits of ,11.5 pg/ml for
male adults and ,4.6 pg/ml for female adults (33). The
application of adult reference data to young children for
whom upper normal limits are rarely, if ever, available from
the manufacturer of the calcitonin assay may yield incorrect
information for children whose seemingly abnormal test
results may actually be within the normal limits for that age
group. This renders it challenging to implement the
calcitonin-based part of the ATA guidelines (Table 1; right
panel) for young children unless calcitonin serum levels are
quite high.
CURRENT CHALLENGES
In our increasingly mobile society, clinical care for MEN2
has become fragmented, with different service providers
caring for one individual at various stages in the disease
process. Geographical dispersion of family members, some
of whom may be living abroad, can add to a screening
program’s difficulty in reaching out to all relatives who may
have inherited the trait running in the family. These issues
frustrated screening efforts directed at all 86 members of a
large French L790F RET family. Of these potential gene
carriers, no more than 22 family members (26%) ended up
being tested despite the authors’ vigorous attempts at
complete ascertainment (34). Moreover, not every newly
identified gene carrier is prepared to share personal genetic
information with his/her next of kin.
This attitude explains why there can be more than one
index patient within an extended RET family whose
members, living in silos as it were, underwent RET
screening after developing MTC independently of one
another. Figure 2 depicts the pedigrees of two unrelated
RET families in whom a longstanding breakdown of
communication had occurred. This disruption delayed the
diagnosis of hereditary MTC in the second index patient by
7 years in the C611F family (Figure 2a) and 19 years in the
C620S family (Figure 2b). This significant delay may have
contributed to our inability to biochemically cure the second
index patient, giving the C-cell disease 7 and 19 additional
years to spread beyond curability. There is a paucity of
research into the reasons behind some gene carriers’
unwillingness to share genetic risk with individuals at risk
within their families. Hypothetical reasons include repres-
sion, feelings of guilt and resentment, emotional distress,
and poor familial interaction.
This is when DNA-based screening, requiring only a
venous blood draw, comes into play. Barring sample mix-
up, the RET gene test confirms or rules out an individual’s
genetic predisposition to MEN2 even before there is any
biochemical or clinical evidence of disease. This is most
relevant in the event of adopted children or broken families
in whom information about the history of the origin family
is sketchy or just unavailable.
However, this unrivaled molecular genetic progress does
not come without a price. DNA-based screening may
occasionally uncover previously unknown RET sequence
variants dubbed ‘‘variants of unknown significance’’ (VUS),
which may represent harmless polymorphisms or patho-
genic mutations. This distinction is difficult, if not impos-
sible, to make when one sole family member is clinically
affected so that there is no demonstrable segregation of the
trait with the disease. This scenario is common in small and
younger families whose members conceivably may not have
been given sufficient time to develop the disease. In this
setting, functional characterization of RET mutant cells in
vitro has been harnessed to generate ancillary evidence
regarding the pathogenicity of unknown sequence variants
in comparison with established RET mutations (35–38). This
experimental approach, albeit promising, will need further
validation before being considered for routine clinical use.
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